BeammWave announced a joint pre-study with Alpha Networks, a fixed wireless access (FWA) challenger,...
The arrival of the first commercial prototype instruments for Prolight’s Psyros Point of Care (POC) ...
Contemplates issuance of SEK 250m bond (500m framework) Refinance of the SEK 250m bond issued in Q4'...
After a soft Q3, PMD Device Solutions (“PMD”) is still aiming for a cash break-even by late 2024 or ...
AcuCort har publicerat bolagets delårsrapport för det tredje kvartalet 2024 och annonserat en företr...
ODI Pharma AB:s (”ODI Pharma” or the ”Company”) latest quarter was affected by import restrictions i...
STENOCARE announced on December 2nd that the company’s premium product, the Astrum oil, has been app...
The US company is both a health insurance and a health care service provider covering more than 10m ...
Ramlösa shipping AB (”Ramlösa” eller ”Bolaget”) har hållit ett högt affärstempo under det tredje kva...
Solwers posted Q3 2024 revenue growth of 21% y/y, entirely driven by acquisitions.
Redeye has a positive view of Tagmaster’s acquisition.
Redeye initiates coverage of SynAct Pharma, a biotech company advancing a novel approach to controll...
VBG Group rapporterade en organisk tillväxtminskning på 11,5 % jämfört med Q3-23, med en omsättning ...
Irisity AB (”Irisity” or ”the Company”) announced, on the 28th of November, the outcome of the right...
Redeye provides a research update following the Q3 report published by Initiator Pharma earlier toda...
Q3 sales are down by 12% compared with Q3 2024 and by some 35% compared with the previous quarter at...
The positive results in Nanexa’s Phase I study for NEX-22, a once-monthly depot formulation of the G...
Redeye shares its initial comments on Ngenic’s Q3 report, published this morning.
Solwers posted Q3 results that were on the weak side on profitability versus Q3 2023.
Redeye returns following Elicera's Q3 report and recent news in the company.
